Search

Displaying results 5121 - 5130 of 10000 in total
  1. Drug

    STC3141

    go.drugbank.com/drugs/DB16475
    Investigational

    STC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.

  2. Drug

    Xamoterol

    go.drugbank.com/drugs/DB13781
    Approved

    Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. … It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.

  3. Drug

    SB-509

    go.drugbank.com/drugs/DB05579
    Investigational

    SB-509 is under investigation in multiple clinical trials for the treatment of Diabetic Neuropathy.

  4. Drug

    Ramoplanin

    go.drugbank.com/drugs/DB04952
    Experimental

    Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.

  5. Drug

    Hyperforin

    go.drugbank.com/drugs/DB01892
    InvestigationalNutraceutical

    Hyperforin is a phytochemical generated by the plants of the Hypericum family. … One of the most important members of this family, due to its medical properties, is _Hypericum perforatum_, also known as St John's wort.

  6. Drug

    Ethyl macadamiate

    go.drugbank.com/drugs/DB11243
    Approved

    Ethyl macadamiate is used in cosmetics and personal care products such as sunscreen, hair care products and skin care products as an emollient and skin conditioning agent. … Ethyl macadamiate is derived from Macadamia terifolia seed oil. It is a non-volatile ester of ethyl alcohol and the fatty acids.

  7. Drug

    ND7001

    go.drugbank.com/drugs/DB05142
    Experimental

    ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. … It is a new type of antidepressant drug with anxiolytic activity.

  8. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  9. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks

  10. Drug

    Adipiplon

    go.drugbank.com/drugs/DB06579
    Investigational

    Adipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.